RVTY Dividends
Revvity, Inc. (RVTY) pays $0.28 in dividends per share, with a current dividend yield of 0.29%.
RVTY Dividend Summary
0.29%
$0.28
13.33%
6.42%
Consecutive Years
0
Next Ex-Dividend Date
Jul 17, 2026
Next Payment Date
Aug 7, 2026
RVTY Dividends per Share (Nominal History)
View full nominal table listThis step chart displays the nominal dividend payouts over time on their actual payment dates, matching the distribution frequency.
RVTY Dividends CAGR Chart
Revvity, Inc. (RVTY)
Annual Dividend History
| Year | Dividend/Share | YoY Growth |
|---|---|---|
| 2026(YTD) | $0.21 | — |
| 2025 | $0.28 | +0.00% |
| 2024 | $0.28 | +0.00% |
| 2023 | $0.28 | +0.00% |
| 2022 | $0.28 | +0.00% |
| 2021 | $0.28 | +0.00% |
| 2020 | $0.28 | +0.00% |
| 2019 | $0.28 | +0.00% |
| 2018 | $0.28 | +0.00% |
| 2017 | $0.28 | +0.00% |
| 2016 | $0.28 | +0.00% |
| 2015 | $0.28 | +0.00% |
| 2014 | $0.28 | +0.00% |
| 2013 | $0.28 | +0.00% |
| 2012 | $0.28 | +0.00% |
| 2011 | $0.28 | +0.00% |
| 2010 | $0.28 | +0.00% |
| 2009 | $0.28 | +0.00% |
| 2008 | $0.28 | +0.00% |
| 2007 | $0.28 | +0.00% |
Quarterly Dividend History
| Quarter | Dividend/Share | YoY Growth |
|---|---|---|
| Q3 2026 | $0.07 | +0.00% |
| Q2 2026 | $0.07 | +0.00% |
| Q1 2026 | $0.07 | +0.00% |
| Q4 2025 | $0.07 | +0.00% |
| Q3 2025 | $0.07 | +0.00% |
| Q2 2025 | $0.07 | +0.00% |
| Q1 2025 | $0.07 | +0.00% |
| Q4 2024 | $0.07 | +0.00% |
| Q3 2024 | $0.07 | +0.00% |
| Q2 2024 | $0.07 | +0.00% |
| Q1 2024 | $0.07 | +0.00% |
| Q4 2023 | $0.07 | +0.00% |
| Q3 2023 | $0.07 | +0.00% |
| Q2 2023 | $0.07 | +0.00% |
| Q1 2023 | $0.07 | +0.00% |
| Q4 2022 | $0.07 | +0.00% |
| Q3 2022 | $0.07 | +0.00% |
| Q2 2022 | $0.07 | +0.00% |
| Q1 2022 | $0.07 | +0.00% |
| Q4 2021 | $0.07 | +0.00% |
| Q3 2021 | $0.07 | +0.00% |
| Q2 2021 | $0.07 | +0.00% |
| Q1 2021 | $0.07 | +0.00% |
| Q4 2020 | $0.07 | +0.00% |
Dividend Yield Metrics
- Current Yield
- 0.29%
- Average Yield (TTM)
- 0.29%
- Average Yield (3Y)
- 0.29%
- Forward Yield on Cost (3Y)
- 0.29%
- Forward Yield on Cost (5Y)
- 0.29%
- Forward Yield on Cost (10Y)
- 0.29%
Payout Ratio Analysis
- Payout Ratio (Current)
- 13.33%
- FCF Payout Ratio
- 6.42%
- Payout Ratio (3Y Avg)
- 10.43%
- Payout Ratio (5Y Avg)
- 7.80%
- FCF Payout (3Y Avg)
- 121.71%
- FCF Payout (5Y Avg)
- 74.71%
An FCF payout above 100% means dividends exceeded the period's free cash flow, often because of temporarily depressed FCF (one-off capex or working-capital swings) rather than an unfunded dividend. Compare against the earnings payout ratio and the multi-year trend before drawing a conclusion.
Dividend Coverage
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh